Lantheus Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Lantheus Holdings, Inc. (LNTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 824.11 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-02-26
- Lantheus Holdings, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 824.11K shares, a 2.24% decline from fiscal 2024.
- Lantheus Holdings, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 842.99K shares, a 18.57% increase from fiscal 2023.
- Lantheus Holdings, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 710.99K shares, a 9.44% increase from fiscal 2022.
- Lantheus Holdings, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 649.67K shares, a 35.05% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|
| 2025-12-31 | 824.11K shares 10-K · filed 2026-02-26 |
| 2024-12-31 | 842.99K shares 10-K · filed 2025-02-26 |
| 2023-12-31 | 710.99K shares 10-K · filed 2024-02-22 |
| 2022-12-31 | 649.67K shares 10-K · filed 2023-02-23 |
| 2021-12-31 | 1.00M shares 10-K · filed 2022-02-24 |
| 2020-12-31 | 786.01K shares 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |